|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar
|
|
2
|
Tamoxifen for early breast cancer: An
overview of the randomised trials. Early Breast Cancer Trialists'
Collaborative Group. Lancet. 351:1451–1467. 1998. View Article : Google Scholar
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burkart C, Arimoto K, Tang T, Cong X, Xiao
N, Liu YC, Kotenko SV, Ellies LG and Zhang DE: Usp18 deficient
mammary epithelial cells create an antitumour environment driven by
hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO
Mol Med. 5:1035–1050. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Potu H, Sgorbissa A and Brancolini C:
Identification of USP18 as an important regulator of the
susceptibility to IFN-alpha and drug-induced apoptosis. Cancer Res.
70:655–665. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo Y, Dolinko AV, Chinyengetere F,
Stanton B, Bomberger JM, Demidenko E, Zhou DC, Gallagher R, Ma T,
Galimberti F, et al: Blockade of the ubiquitin protease UBP43
destabilizes transcription factor PML/RARα and inhibits the growth
of acute promyelocytic leukemia. Cancer Res. 70:9875–9885. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan M, Luo JK, Ritchie KJ, Sakai I,
Takeuchi K, Ren R and Zhang DE: Ubp43 regulates BCR-ABL
leukemogenesis via the type 1 interferon receptor signaling. Blood.
110:305–312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sgorbissa A, Tomasella A, Potu H, Manini I
and Brancolini C: Type I IFNs signaling and apoptosis resistance in
glioblastoma cells. Apoptosis. 16:1229–1244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shahidul Makki M, Cristy Ruteshouser E and
Huff V: Ubiquitin specific protease 18 (Usp18) is a WT1
transcriptional target. Exp Cell Res. 319:612–622. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo Y, Chinyengetere F, Dolinko AV,
Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D,
Freemantle SJ, et al: Evidence for the ubiquitin protease UBP43 as
an antineoplastic target. Mol Cancer Ther. 11:1968–1977. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tan XF and Xia F: Long-term fatigue state
in postoperative patients with breast cancer. Chin J Cancer Res.
26:12–16. 2014.PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
13
|
Tolba MF, Esmat A, Al-Abd AM, Azab SS,
Khalifa AE, Mosli HA, Abdel-Rahman SZ and Abdel-Naim AB: Caffeic
acid phenethyl ester synergistically enhances docetaxel and
paclitaxel cytotoxicity in prostate cancer cells. IUBMB Life.
65:716–729. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duex JE, Comeau L, Sorkin A, Purow B and
Kefas B: Usp18 regulates epidermal growth factor (EGF) receptor
expression and cancer cell survival via microRNA-7. J Biol Chem.
286:25377–25386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duex JE and Sorkin A: RNA interference
screen identifies Usp18 as a regulator of epidermal growth factor
receptor synthesis. Mol Biol Cell. 20:1833–1844. 2009. View Article : Google Scholar :
|
|
16
|
Wu J, Lee SW, Zhang X, Han F, Kwan SY,
Yuan X, Yang WL, Jeong YS, Rezaeian AH, Gao Y, et al: Foxo3a
transcription factor is a negative regulator of Skp2 and Skp2 SCF
complex. Oncogene. 32:78–85. 2013. View Article : Google Scholar :
|
|
17
|
Chan CH, Li CF, Yang WL, Gao Y, Lee SW,
Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, et al: The Skp2-SCF
E3 ligase regulates Akt ubiquitination, glycolysis, herceptin
sensitivity, and tumorigenesis. Cell. 149:1098–1111. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Malakhova O, Malakhov M, Hetherington C
and Zhang DE: Lipopolysaccharide activates the expression of
ISG15-specific protease UBP43 via interferon regulatory factor 3. J
Biol Chem. 277:14703–14711. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Malakhov MP, Malakhova OA, Kim KI, Ritchie
KJ and Zhang DE: UBP43 (USP18) specifically removes ISG15 from
conjugated proteins. J Biol Chem. 277:9976–9981. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
François-Newton V, Magno de Freitas
Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler
J, Pellegrini S and Uzé G: USP18-based negative feedback control is
induced by type I and type III interferons and specifically
inactivates interferon α response. PLoS One. 6:e222002011.
View Article : Google Scholar
|
|
21
|
Ritchie KJ, Hahn CS, Kim KI, Yan M,
Rosario D, Li L, de la Torre JC and Zhang DE: Role of ISG15
protease UBP43 (USP18) in innate immunity to viral infection. Nat
Med. 10:1374–1378. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang Z, Xian H, Hu J, Tian S, Qin Y, Wang
RF and Cui J: USP18 negatively regulates NF-κB signaling by
targeting TAK1 and NEMO for deubiquitination through distinct
mechanisms. Sci Rep. 5:127382015. View Article : Google Scholar
|
|
23
|
Zhang M, Zhang MX, Zhang Q, Zhu GF, Yuan
L, Zhang DE, Zhu Q, Yao J, Shu HB and Zhong B: USP18 recruits USP20
to promote innate antiviral response through deubiquitinating
STING/MITA. Cell Res. 26:1302–1319. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schulz S, Chachami G, Kozaczkiewicz L,
Winter U, Stankovic-Valentin N, Haas P, Hofmann K, Urlaub H, Ovaa
H, Wittbrodt J, et al: Ubiquitin-specific protease-like 1 (USPL1)
is a SUMO isopeptidase with essential, non-catalytic functions.
EMBO Rep. 13:930–938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ritchie KJ, Malakhov MP, Hetherington CJ,
Zhou L, Little MT, Malakhova OA, Sipe JC, Orkin SH and Zhang DE:
Dysregulation of protein modification by ISG15 results in brain
cell injury. Genes Dev. 16:2207–2212. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Komander D, Clague MJ and Urbé S: Breaking
the chains: Structure and function of the deubiquitinases. Nat Rev
Mol Cell Biol. 10:550–563. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rajaram P, Chandra P, Ticku S, Pallavi BK,
Rudresh KB and Mansabdar P: Epidermal growth factor receptor: Role
in human cancer. Indian J Dent Res. 28:687–694. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai Z and Liu Q: Cell cycle regulation in
treatment of breast cancer. Adv Exp Med Biol. 1026:251–270. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo Y, Xu DQ, Dong HY, Zhang B, Liu Y, Niu
W, Dong MQ and Li ZC: Tanshinone IIA inhibits hypoxia-induced
pulmonary artery smooth muscle cell proliferation via
Akt/Skp2/p27-associated pathway. PLoS One. 8:e567742013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Radke S, Pirkmaier A and Germain D:
Differential expression of the F-box proteins Skp2 and Skp2B in
breast cancer. Oncogene. 24:3448–3458. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao D, Inuzuka H, Tseng A, Chin RY, Toker
A and Wei W: Phosphorylation by Akt1 promotes cytoplasmic
localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction.
Nat Cell Biol. 11:397–408. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang JY and Hung MC: A new fork for
clinical application: Targeting forkhead transcription factors in
cancer. Clin Cancer Res. 15:752–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Harper KL, Sosa MS, Entenberg D, Hosseini
H, Cheung JF, Nobre R, Avivar-Valderas A, Nagi C, Girnius N, Davis
RJ, et al: Mechanism of early dissemination and metastasis in
Her2+ mammary cancer. Nature. 540:588–592. 2016.
View Article : Google Scholar
|
|
34
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome - biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Teschendorff AE, Gao Y, Jones A, Ruebner
M, Beckmann MW, Wachter DL, Fasching PA and Widschwendter M: DNA
methylation outliers in normal breast tissue identify field defects
that are enriched in cancer. Nat Commun. 7:104782016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Malhotra S, Bustamante MF, Pérez-Miralles
F, Rio J, Ruiz de Villa MC, Vegas E, Nonell L, Deisenhammer F,
Fissolo N, Nurtdinov RN, et al: Search for specific biomarkers of
IFNβ bioactivity in patients with multiple sclerosis. PLoS One.
6:e236342011. View Article : Google Scholar
|
|
37
|
Malhotra S, Morcillo-Suárez C, Nurtdinov
R, Rio J, Sarro E, Moreno M, Castilló J, Navarro A, Montalban X and
Comabella M: Roles of the ubiquitin peptidase USP18 in multiple
sclerosis and the response to interferon-β treatment. Eur J Neurol.
20:1390–1397. 2013. View Article : Google Scholar : PubMed/NCBI
|
